🔍 Fact of the day 🔍

Clinical trials are going digital.

According to Grand View Research, the clinical trial software (‘eClinical solutions’) market will expand at a compound annual growth rate (CAGR) of 13.6% from 2022 to 2030.

Triall's eClinical platform is designed to serve and connect all key stakeholders involved in clinical research.

Source: bit.ly/3AQfxLg

⚡️ Trade $TRL at bit.ly/tradeTRL

🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1597213453697286144?s=20&t=6OK7m48Z4p5gNaQPaTCIeA

#blockchainforhealth #TRL

Don’t miss tomorrow’s AMA 📺💬

In last month’s video AMA, Hadil explained how eClinical tools have transformed clinical trial operations over the years.

Tomorrow (Nov 30) at 13:00 UTC, Triall will host its 9th video AMA on YouTube, answering both live and pre-submitted questions from the Triall community.

Join the live session to learn more about our industry, eClinical platform, and blockchain-enabled vision for clinical research.

🎙 AMA Guests
- Hadil Es-Sbai, Chief Executive Officer
- Arno Bisschop, Chief Medical Officer
- Raymond van der Waal, Head of Strategic Partnerships

📬 Submit your questions today
We invite you all to submit your questions using this link: bit.ly/TRLvidAMA9

The 5 best questions get $50 worth of $TRL tokens💰

See you tomorrow!

🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1597539554281820161?s=20&t=NAfkTnfwrcZd1QDmj8KxXw

#blockchainforhealth #TRL

And we’re live once again! 🚨📺💬

Tune in to this month’s live video AMA 👇
https://youtu.be/A2mWxs-JKyg

🔍 Fact of the day 🔍

According to a study by IQVIA, decentralised clinical trials (DCTs) can realise a 54% reduction in protocol deviations.

Protocol deviations can result in patient safety risks, costly protocol amendments, and lengthy trial delays.

Triall offers a range of DCT tools that help clinical research professionals with maintaining protocol compliance throughout all of their core study activities.

Source: bit.ly/3BxPXev

⚡️ Trade $TRL at bit.ly/tradeTRL

🗣 Help spread the news on Twitter:
https://twitter.com/triallofficial/status/1599734527559016448?s=20&t=GXgTNZ7IgAi3r4qAtdhUTA

#blockchainforhealth #TRL

Announcing the video AMA winners 🏆📺💬

Last week, Triall hosted its 9th monthly community AMA live on YouTube.

Today, we’re happy to announce the AMA winners who posted the 5 best questions for the team.

AMA winner list
@Cally001
@AdiBila_111
@Defi58
@Rebecca2_14
@Faith_inChaos

How do I redeem my reward?
Please contact @rxvdwaal to share your BEP-20 address.

Missed the live session?
Check out the full recording: youtu.be/A2mWxs-JKyg

When is the next AMA?
Our next video AMA will be hosted by the end of this month.

🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1600503415234248708?s=20&t=FML01lnqp3-AMew9JSwD9w

#blockchainforhealth #TRL

🔍 Fact of the day 🔍

According to Tufts CSDD, 119 protocol deviations occur on average in a typical Phase 3 clinical trial.

These protocol deviations are the top reason for clinical trial enforcement actions by regulators such as the FDA.

Triall offers an end-to-end eClinical platform that harmonises and enforces protocol compliance across all participating research sites.

Source: https://bit.ly/3xV0YVc

🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1602274606651478018?s=20&t=Q07e7kvjg6vyomsHHsOrHg

#blockchainforhealth #TRL

Join us in the last AMA of 2022 📺💬

Dear Triallians,

As we approach the end of this year, we wanted to take a moment to express our deep gratitude for your continued support & belief in our mission.

Next week, we will reflect on some of the highlights of 2022 while also providing a sneak preview of what’s to come in 2023.

As part of this, we’ll also be hosting our monthly AMA to answer questions on our current objectives for Triall and $TRL.

We therefore invite you to join us on Dec 22 at 15:00 UTC as we host our last AMA of the year (and 10th edition in this series).

🎙 AMA Guests
- Hadil Es-Sbai, Chief Executive Officer
- Niels Klomp, Chief Technology Officer
- Arno Bisschop, Chief Medical Officer
- Raymond van der Waal, Head of Strategic Partnerships

📬 AMA Questions
Submit your questions here: bit.ly/TRLvidAMA10

The 5 best questions get $50 in TRL tokens💰

🗣 Twitter:
https://twitter.com/triallofficial/status/1603738633743355906?s=20&t=kQBD-CDkhs7UAnNFp5TIMA

#blockchainforhealth #TRL

🔍 Fact of the day 🔍

According to a study by IQVIA, Decentralised Clinical Trials (DCTs) can realise a 78% reduction in recruiting time, measured by time from first patient in (FPI) to last patient in (LPI).

Triall offers a range of DCT tools that streamline and promote patient engagement throughout the clinical study.

Source: https://eu1.hubs.ly/H02q4ty0

⚡️ Trade $TRL at bit.ly/tradeTRL

🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1604823867406557186?s=20&t=aw12QtdUgqehav40iyYZtQ

#blockchainforhealth #TRL

Our last AMA of 2022 📺💬

Want to learn more about our latest developments and objectives for 2023?

Join our last community AMA of the year (and 10th edition in this series), which will take place on December 22 at 16:00 UTC on YouTube.

🎙 AMA Guests
- Hadil Es-Sbai, Chief Executive Officer
- Niels Klomp, Chief Technology Officer
- Arno Bisschop, Chief Medical Officer
- Raymond van der Waal, Head of Strategic Partnerships

📬 AMA Questions
Submit your questions here: bit.ly/TRLvidAMA10

The 5 best questions get $50 in TRL tokens💰

🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1605190032846905344?s=20&t=r40rnZvj6y6lHX_fqEXuBA

#blockchainforhealth #TRL

End of the year message by Hadil 🎄

Dear Triallians,

As we are nearing the end of 2022, we can look back on a dynamic and fruitful year for Triall.

We'd like to conclude this year with a video message by Triall CEO Hadil, who walks you through our highlights while also providing a brief outlook on what's to come in 2023.

Questions related to our goals and objectives for 2023? Join our live AMA on YouTube, which starts in a few minutes.

Happy holidays!

👉📺 Video link: https://www.youtube.com/watch?v=s7FWYdqAtmA

🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1605954369605619712?s=20&t=-DEiZLbzT9GcZH8d1sk-BA

#blockchainforhealth #TRL

And we’re live once again! 🚨📺💬

Tune in to this month’s live video AMA 👇
https://www.youtube.com/watch?v=6qAp41EdMCA

🔍 Fact of the day 🔍

According to the IQVIA Institute, 300 new molecular entities (‘NMEs’) are expected to be approved between 2022 and 2026. This translates into 60 NMEs per year compared to the 53 NMEs per year average over the past decade.

The influx of NMEs demonstrates the need for specialised service providers who can help perform reliable and cost-efficient clinical trials.

Triall’s eClinical platform is designed to support any therapeutic area, any trial type (decentralized, hybrid, site-based), and any trial phase (I-IV). We offer a modular and fully-integrated suite of software solutions that can be configured to specific needs and budgets.

⚡️ Trade $TRL at bit.ly/tradeTRL

🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1607360580934852608?s=20&t=Ty8KS4aJh9V6j9U0a5Nn8w

#blockchainforhealth #TRL

Announcing the AMA winners 🏆📺💬

Last month, Triall hosted its 10th monthly community AMA live on YouTube.

Today, we’re happy to announce the AMA winners who posted the 5 best questions for the team.

AMA winner list
@alts_crypto
@Umrsha
@Felix_BL
@Chris15_y
@OK_Renegade

How do I redeem my reward?
Please contact @rxvdwaal to share your BEP-20 address.

Missed the live session?
Check out the full recording: youtube.com/watch?v=6qAp41EdMCA

When is the next AMA?
Our next video AMA will be hosted by the end of this month.

🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1610622632881262593?s=20&t=psVWmmdoZjhIDofGtK-TJw

#blockchainforhealth #TRL

Launching the new Triall website 👩🏽‍💻

We’re thrilled to announce the launch of our new website!

Our redesigned website helps you navigate all of our software products, including EDC, ePRO, eConsent, eTMF, CTMS, virtual visits, wearable integration, and more.

Moreover, it includes a brand new blog section that hosts a selection of articles and news on industry trends, changing regulations, and emerging technologies in clinical trials.

Take a look and let us know what you think!

👉 Website link: triall.io

🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1611350408936714246?s=20&t=VYZKJV4S4XqsdM9scV7XCA

#blockchainforhealth #TRL

🔍 Fact of the day 🔍

According to an industry-wide survey by Veeva, 87% of sponsors and CROs are using or planning to use decentralized clinical trials (DCTs) within the next 12 months.

Despite growing adoption of DCT tools, fragmented technology is mentioned as a key issue that presents challenges related to site adoption, patient burden, and data collection & reporting.

Triall addresses this issue by offering purpose-built DCT tools as a fully-integrated part of its end-to-end eClinical platform.

Source: https://eu1.hubs.ly/H02wxWw0

⚡️ Trade $TRL at bit.ly/tradeTRL

🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1612434012580052994?s=20&t=VrSYw2AkTCl5s3-a_FN3nw

#blockchainforhealth #TRL

Decentralising clinical research: the implications of blockchain & SSI 🌐

Clinical trials have become increasingly decentralised over the past 20 years. This trend is driven by eClinical tools, such as ePRO and eConsent, which migrate many study procedures outside the hospital.

However, while data capture & patient management have decentralised, data ownership is still very centralised. Study data is captured for the purpose of 1 study only, with the sponsor as its sole owner.

After 2 decades of eClinical innovation, we've now arrived at the next wave of decentralisation. One that provides patients with ownership over their data while also promoting the reuse of that data.

Enabling this new form of decentralisation will require a cybersecure, privacy-preserving, and interoperable infrastructure for distributing ownership.

👉 Here we explain the role of blockchain and SSI in realising this future: twitter.com/triallofficial/status/1613513620993806337?s=20&t=-kpktV5uNuuGD3LZ7ebtww

Fact of the day 🔍

Only 56% of sponsors and CROs report decentralised trials have had a positive impact on patient convenience and retention.

The most commonly heard argument is that decentralised trials often introduce multiple patient-facing applications, thereby adding unnecessary complexity for patients.

Triall addresses this issue by offering a single unified platform with integrated eConsent, ePRO, and virtual visits tools. This ensures patients only need to use a single application throughout the study.

Source: https://eu1.hubs.ly/H02BnpN0

⚡️ Trade $TRL at bit.ly/tradeTRL

🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1614970727903514636?s=20&t=H9oRtPantadrgPro-71xKg

#blockchainforhealth #TRL

In the news: only 1 of 25 cancer drug developers fairly included minority patients 🗞

Despite policy efforts to improve patient diversity in clinical research, under-representation of women, older adults, and racial & ethnical minorities remains a persistent problem.

A recent study published in the BMJ, developed baseline quality measures for fair inclusion in clinical research, capturing transparency of patient demographics & inclusion of under-represented groups.

After applying these quality measures on 59 cancer drugs approved by the FDA, the study concluded only 1/25 sponsor companies scored well on both transparency & representation scores, signalling a significant need for improvement.

At Triall, we support sponsors with accessing a more diverse patient pool through tools such as eConsent & ePRO, and through patient recruitment services offered by our partner network.

👉 More info: twitter.com/triallofficial/status/1616061853020426243?s=20&t=3PN-H9JAOE1MbSVCP7GUWg

#blockchainforhealth #TRL

Fact of the day 🔍

95% of sponsors and CROs have initiatives in place to address the operational challenges that originated from the rapid adoption of decentralised trial methods.

Top priorities include reducing site burden and improving data sharing & collaboration.

At Triall, we support the implementation of hybrid and decentralised trials by offering a unified single-point access platform that can be used by sponsors, CROs, sites, and patients.

Source: veeva.com/resources/veeva-digital-clinical-trials-survey-report/

⚡️ Trade $TRL at bit.ly/tradeTRL

🗣 Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1617507441599553538?s=20&t=SK0VBD0Pr8qBDz0bgHBQQg

#blockchainforhealth #TRL